Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study

BACKGROUND: Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive (Pt-S) ovarian cancer (OC). The Rucaparib Access Programme (RAP) was designed to provide early access to rucaparib for the above-mentioned indication, as well a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yubero, Alfonso, Barquín, Aranzazu, Estévez, Purificación, Pajares, Bella, Sánchez, Luisa, Reche, Piedad, Alarcón, Jesús, Calzas, Julia, Gaba, Lydia, Fuentes, José, Santaballa, Ana, Salvador, Carmen, Manso, Luis, Herrero, Ana, Taus, Álvaro, Márquez, Raúl, Madani, Julia, Merino, María, Marquina, Gloria, Casado, Victoria, Constenla, Manuel, Gutiérrez, María, Dosil, Alba, González-Martín, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644462/
https://www.ncbi.nlm.nih.gov/pubmed/36348385
http://dx.doi.org/10.1186/s12885-022-10191-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644462/
https://www.ncbi.nlm.nih.gov/pubmed/36348385
http://dx.doi.org/10.1186/s12885-022-10191-5

Ejemplares similares